Cargando…
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches
PURPOSE: Nitroglycerin (NTG) is a vasodilating drug, which increases tumor blood flow and consequently decreases hypoxia. Therefore, changes in [18F] fluorodeoxyglucose positron emission tomography ([18F]FDG PET) uptake pattern may occur. In this analysis, we investigated the feasibility of [18F]FDG...
Autores principales: | de Jong, Evelyn E. C., van Elmpt, Wouter, Leijenaar, Ralph T. H., Hoekstra, Otto S., Groen, Harry J. M., Smit, Egbert F., Boellaard, Ronald, van der Noort, Vincent, Troost, Esther G. C., Lambin, Philippe, Dingemans, Anne-Marie C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121177/ https://www.ncbi.nlm.nih.gov/pubmed/27600280 http://dx.doi.org/10.1007/s00259-016-3498-y |
Ejemplares similares
-
The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis
por: Leijenaar, Ralph T.H., et al.
Publicado: (2015) -
(18)F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) – A prospective externally validated study
por: Carvalho, Sara, et al.
Publicado: (2018) -
Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022) -
A Case of Biphasic Pulmonary Blastoma Treated with Carboplatin and Paclitaxel plus Bevacizumab
por: Sakata, Shinya, et al.
Publicado: (2015) -
Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
por: Klavans, Madison R., et al.
Publicado: (2020)